text
"['\n1. 요약재무정보\n당사는 2018년 9월 19일 발표된 [제약ㆍ바이오 기업의 연구개발비 회계처리 관련 감독지침]을 고려, 개발비 자산화 시점의 회계처리 오류(무형자산 과대계상 및 경상연구개발비 과소계상 등)를 수정하였으며, 이에 따라 제28기(전전기) 재무재표는 소급 재작성되었습니다\n가. 요약연결재무정보\n(단위: 원)\n구 분\n제30기\n제29기\n제28기\n(2020년 12월말)\n(2019년 12월말)\n(2018년 12월말)\n[유동자산]\n2,517,748,951,908\xa0\n1,787,340,254,600\n1,664,478,918,682\n\xa0ㆍ현금및현금성자산\n684,293,887,404\xa0\n546,137,583,490\n410,547,608,852\n\xa0ㆍ단기금융자산\n14,034,380,800\xa0\n81,681,590,783\n121,636,304,845\n\xa0ㆍ매출채권\n1,252,394,564,236\xa0\n814,370,251,982\n807,711,314,915\n\xa0ㆍ기타수취채권\n63,321,890,588\xa0\n12,372,205,267\n124,267,624,254\n\xa0ㆍ재고자산\n385,578,700,802\xa0\n308,934,257,868\n163,114,412,936\n\xa0ㆍ당기법인세자산\n-\xa0\n-\n9,523,563,778\n\xa0ㆍ기타유동자산\n118,125,528,078\xa0\n23,844,365,210\n27,678,089,102\n[비유동자산]\n2,529,946,750,136\xa0\n2,106,351,351,846\n1,876,147,755,272\n\xa0ㆍ장기금융자산\n31,346,052,415\xa0\n17,629,052,511\n18,989,084,041\n\xa0ㆍ장기기타수취채권\n10,138,443,975\xa0\n10,733,643,020\n10,287,886,409\n\xa0ㆍ관계기업투자\n48,026,573,643\xa0\n47,841,529,392\n28,003,078,925\n\xa0ㆍ유형자산\n946,280,260,465\xa0\n923,592,891,742\n881,437,749,875\n\xa0ㆍ무형자산\n1,430,508,993,379\xa0\n1,040,013,545,677\n922,339,536,489\n\xa0ㆍ기타비유동자산\n34,658,542,248\xa0\n43,229,409,217\n15,090,419,533\n\xa0ㆍ이연법인세자산\n28,987,884,011\xa0\n23,311,280,287\n-\n자산총계\n5,047,695,702,044\xa0\n3,893,691,606,446\n3,540,626,673,954\n[유동부채]\n1,056,766,920,798\xa0\n657,225,837,904\n678,087,471,395\n[비유동부채]\n535,773,979,083\xa0\n329,507,580,221\n229,761,340,951\n부채총계\n1,592,540,899,881\xa0\n986,733,418,125\n907,848,812,346\n[자본금]\n134,997,805,000\xa0\n128,337,853,000\n125,456,133,000\n[주식발행초과금]\n812,155,732,299\xa0\n786,358,490,538\n761,047,500,208\n[이익잉여금]\n2,501,989,315,478\xa0\n1,996,890,683,771\n1,701,825,879,780\n[기타포괄손익누계액]\n6,298,419,403\xa0\n3,000,227,548\n9,970,124,880\n[기타자본항목]\n(120,189,778,998)\n(120,432,914,312)\n(74,277,317,105)\n[비지배지분]\n119,903,308,981\xa0\n112,803,847,776\n108,755,540,845\n자본총계\n3,455,154,802,163\xa0\n2,906,958,188,321\n2,632,777,861,608\n(2020.01.01~2020.12.31)\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n매출액\n1,849,115,532,111\n1,128,459,877,886\n982,074,959,799\n영업이익\n712,106,830,453\n378,058,980,939\n338,694,787,468\n법인세비용차감전순이익\n650,681,486,511\n378,557,786,804\n317,725,828,715\n당기순이익\n519,232,380,257\n297,969,202,613\n253,563,110,762\n\xa0ㆍ지배기업소유주지분\n511,289,004,038\n297,556,854,991\n261,841,768,570\n\xa0ㆍ비지배지분\n7,943,376,219\n412,347,622\n(8,278,657,808)\n\xa0ㆍ기본주당이익\n3,825\n2,229\n1,960\n연결에 포함된 회사수\n10\n10\xa0\n8\xa0\n나. 요약재무정보\n(단위: 원)\n구 분\n제30기\n제29기\n제28기\n(2020년 12월말)\n(2019년 12월말)\n(2018년 12월말)\n[유동자산]\n2,295,458,368,802\n1,612,955,252,559\n1,482,507,600,161\n\xa0ㆍ현금및현금성자산\n615,216,683,989\n526,092,843,365\xa0\n399,558,425,745\n\xa0ㆍ단기금융자산\n10,034,380,800\n79,113,846,512\xa0\n121,636,304,845\n\xa0ㆍ매출채권\n1,139,308,334,817\n690,252,563,176\xa0\n689,472,264,429\n\xa0ㆍ기타수취채권\n81,332,323,881\n25,476,236,632\xa0\n123,885,214,981\n\xa0ㆍ재고자산\n335,155,395,301\n270,940,010,550\xa0\n125,915,033,826\n\xa0ㆍ기타유동자산\n114,411,250,014\n21,079,752,324\xa0\n22,040,356,335\n[비유동자산]\n2,513,241,368,455\n2,095,612,427,097\n1,925,650,130,627\n\xa0ㆍ장기금융자산\n30,413,459,273\n15,406,459,369\xa0\n17,407,490,899\n\xa0ㆍ장기기타수취채권\n16,138,373,036\n9,618,771,557\xa0\n9,141,484,165\n\xa0ㆍ종속기업및관계기업투자\n631,938,696,277\n313,849,033,448\xa0\n286,212,166,532\n\xa0ㆍ유형자산\n695,641,290,578\n701,428,195,334\xa0\n677,870,722,592\n\xa0ㆍ무형자산\n1,114,756,445,993\n1,019,552,829,643\xa0\n914,462,126,420\n\xa0ㆍ투자부동산\n-\n2,918,466,663\xa0\n5,982,493,446\n\xa0ㆍ기타비유동자산\n24,353,103,298\n32,838,671,083\xa0\n14,573,646,573\n자산총계\n4,808,699,737,257\n3,708,567,679,656\xa0\n3,408,157,730,788\n[유동부채]\n900,571,681,471\n517,564,388,814\n548,121,290,075\n[비유동부채]\n459,265,660,740\n286,291,312,657\n218,455,704,094\n부채총계\n1,359,837,342,211\n803,855,701,471\n766,576,994,169\n[자본금]\n134,997,805,000\n128,337,853,000\xa0\n125,456,133,000\n[주식발행초과금]\n812,155,732,299\n786,358,490,538\xa0\n761,047,500,208\n[이익잉여금]\n2,616,077,813,546\n2,114,638,598,135\xa0\n1,830,849,456,118\n[기타포괄손익누계액]\n13,208,899,479\n2,590,862,595\xa0\n5,011,173,208\n[기타자본항목]\n(127,577,855,278)\n(127,213,826,083)\n(80,783,525,915)\n자본총계\n3,448,862,395,046\n2,904,711,978,185\n2,641,580,736,619\n종속ㆍ관계ㆍ공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n(2020.01.01~2020.12.31)\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n매출액\n1,689,786,996,813\n981,870,268,852\n861,884,226,306\n영업이익\n703,303,610,768\n359,917,605,596\n334,976,430,311\n법인세비용차감전순이익\n643,418,343,917\n365,633,013,229\n312,274,618,195\n당기순이익\n507,799,528,411\n286,281,193,017\n254,360,949,995\n\xa0ㆍ기본주당이익\n3,799\n2,144\n1,904\n']"
